Endovastec(SH:688016) Xin Lang Cai Jing·2025-10-30 02:01Group 1 - Core viewpoint: Xinmai Medical (688016.SH) reported its Q3 2025 results, highlighting significant institutional investor interest with 20 institutions holding a total of 58.3275 million shares, representing 47.32% of the total share capital [1] - The top ten institutional investors collectively hold 47.20% of the shares, with a 0.59 percentage point increase from the previous quarter [1] - Major institutional investors include MicroPort Endovascular CHINA Corp. Limited and Hong Kong Central Clearing Limited among others [1] Group 2 - In the public fund sector, one fund, Xinhua Strategic Emerging Industries Flexible Allocation Mixed Fund, increased its holdings, while two funds, Huabao CSI Medical ETF and Southern CSI 1000 ETF, reduced their holdings by 0.26% [2] - Nine new public funds were disclosed this period, including Guotai Junan Multi-Strategy Flexible Allocation Mixed A and others [2] - A total of 184 public funds were not disclosed this period, including notable funds like Bosera Sci-Tech 100 ETF and others [2] Group 3 - From the foreign investment perspective, one new foreign institution, Hong Kong Central Clearing Limited, was disclosed this period [3]